Systemic inflammation in COPD in relation to smoking status

Multidisciplinary Respiratory Medicine

Volumn 6, Issue 4, 2011, Pages 214-219

  Serapinas, Danielius ^a,b   Narbekovas, Andrius ^b   Juskevicius, Jonas ^b   Sakalauskas, Raimundas ^a  

^a LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^b MYKOLAS ROMERIS UNIVERSITY   (Lithuania)

Author keywords

Alpha 1 antitrypsin; COPD; Inflammatory markers

Indexed keywords

ALPHA 1 ANTITRYPSIN; C REACTIVE PROTEIN; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 1; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; SMOKING; SPIROMETRY; DISEASE ASSOCIATION; MIDDLE AGED; PROTEIN DETERMINATION; SMOKING HABIT;

EID: 80054047906     PISSN: 1828695X     EISSN: 20496958     Source Type: Journal    
DOI: 10.1186/2049-6958-6-4-214     Document Type: Article

References (40)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2006. Global strategy for the diagnosis, management, and prevention of COPD. Executive Summary. http://www.goldcopd.org.
2. Willemse BW, Postma DS, Timens W, ten Hacken NH. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J 2004;23:464-476. (Pubitemid 38344387)
3. Chung KF. Cytokines as targets in chronic obstructive pulmonary disease. Curr Drug Targets 2006;7:675-681. (Pubitemid 43827263)
4. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574-580 (Pubitemid 38901515)
5. Garcia-Rio F, Miravitlles M, Soriano JB, Muñoz L, Duran- Tauleria E, Sánchez G, Sobradillo V, Ancochea J; EPI-SCAN Steering Committee. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res 2010;11:63.
6. Pinto-Plata VM, Livnat G, Girish M, Cabral H, Masdin P, Linacre P, Dew R, Kenney L, Celli BR. Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD. Chest 2007;131:37-43. (Pubitemid 46122972)
7. Karadag F, Kirdar S, Karul AB, Ceylan E. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. Eur J Intern Med 2008;19:104-108.
8. Bradley JR. TNF-mediated inflammatory disease. J Pathol 2008;214:149-160. (Pubitemid 351160153)
9. Mukhopadhyay S, Hoidal JR, Mukherjee TK. Role of TNFalpha in pulmonary pathophysiology. Respir Res 2006;7:125.
10. Carp H, Miller F, Hoidal JR, Janoff A. Potential mechanism of emphysema: alpha1-proteinase inhibitor recovered from lungs of cigarette smokers contains oxidized methionine and has decreased elastase inhibitory capacity. Proc Natl Acad Sci USA 1982;79:2041-2045. (Pubitemid 12088565)
11. van der Vaart H, Postma DS, Timens W, Hylkema MN, Willemse BW, Boezen HM, Vonk JM, de Reus DM, Kauffman HF, ten Hacken NH. Acute effects of cigarette smoking on inflammation in healthy intermittent smokers. Respir Res 2005;6:22.
12. Janciauskiene SM, Nita IM, Stevens T. Alpha1-antitrypsin, old dog, new tricks. Alpha1-antitrypsin exerts in vitro antiinflammatory activity in human monocytes by elevating cAMP. J Biol Chem 2007;282:8573-8582. (Pubitemid 47093518)
13. Gorber SC, Schofield-Hurwitz S, Hardt J, Levasseur G, Tremblay M. The accuracy of self-reported smoking: a systematic review of the relationship between self-reported and cotinine-assessed smoking status. Nicotine Tob Res 2009;11:12-24.
14. Dolcini MM, Adler NE, Lee P, Bauman KE. An assessment of the validity of adolescent self-reported smoking using three biological indicators. Nicotine Tob Res 2002;5:473-483. (Pubitemid 37081128)
15. Senn O, Russi EW, Schindler C, Imboden M, von Eckardstein A, Brändli O, Zemp E, Ackermann-Liebrich U, Berger W, Rochat T, Luisetti M, Probst-Hensch NM; SAPALDIA Team. Circulating alpha1-antitrypsin in the general population: determinants and association with lung function. Respir Res 2008;9:35.
16. Stockley RA, Burnett D. Alpha-1-antitrypsin and leukocyte elastase in infected and noninfected sputum. Am Rev Respir Dis 1979;120:1081-1086. (Pubitemid 10218496)
17. Owen CA, Campbell EJ. Extracellular proteolysis: new paradigms for an old paradox. J Lab Clin Med 1999;134:341- 351.
18. Meyer KC, Rosenthal NS, Soergel P, Peterson K. Neutrophils and low-grade inflammation in the seemingly normal aging human lung. Mech Ageing Dev 1998;104:169-181. (Pubitemid 28457047)
19. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574-580. (Pubitemid 38901515)
20. Silverman EK, Province MA, Rao DC, Pierce JA, Campbell EJ. A family study of the variability of pulmonary function in alpha 1-antitrypsin deficiency. Quantitative phenotypes. Am Rev Respir Dis 1990;142:1015-1021. (Pubitemid 20384352)
21. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514-1519. (Pubitemid 36378490)
22. Daniels JM, Schoorl M, Snijders D, Knol DL, Lutter R, Jansen HM, Boersma WG. Procalcitonin versus C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD. Chest 2010;138:1108-1115.
23. Godoy I, Campana AO, Geraldo RR, Padovani CR, Paiva SA. Cytokines and dietary energy restriction in stable chronic obstructive pulmonary disease patients. Eur Respir J 2003;22:920-925. (Pubitemid 37540642)
24. Dentener MA, Creutzberg EC, Schols AM, Mantovani A, van't Veer C, Buurman WA, Wouters EF. Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. Thorax 2001;56:721-726. (Pubitemid 32831700)
25. Baraldo S, Turato G, Badin C, Bazzan E, Beghé B, Zuin R, Calabrese F, Casoni G, Maestrelli P, Papi A, Fabbri LM, Saetta M. Neutrophilic infiltration within the airway smooth muscle in patients with COPD. Thorax 2004;59:308-312. (Pubitemid 38496748)
26. Battaglia S, Mauad T, van Schadewijk AM, Vignola AM, Rabe KF, Bellia V, Sterk PJ, Hiemstra PS. Differential distribution of inflammatory cells in large and small airways in smokers. J Clin Pathol 2007;60:907-911. (Pubitemid 47234438)
27. Vernooy JH, Küçükaycan M, Jacobs JA, Chavannes NH, Buurman WA, Dentener MA, Wouters EF. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med 2002;166:1218-1224. (Pubitemid 35222599)
28. Quint JK, Wedzicha JA. The neutrophil in chronic obstructive pulmonary disease. J Allergy Clin Immunol 2007;119:1065-1071. (Pubitemid 46654162)
29. Barceló B, Pons J, Ferrer JM, Sauleda J, Fuster A, Agustí AG. Phenotypic characterization of T-lymphocytes in COPD: abnormal CD4+CD25+ regulatory T-lymphocyte response to tobacco smoking. Eur Respir J 2008;31:555-562.
30. Barnes PJ, Chowdhury B, Kharitonov SA, Magnussen H, Page CP, Postma D, Saetta M. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174:6-14. (Pubitemid 43955238)
31. Gamble E, Grootendorst DC, Hattotuwa K, O'Shaughnessy T, Ram FS, Qiu Y, Zhu J, Vignola AM, Kroegel C, Morell F, Pavord ID, Rabe KF, Jeffery PK, Barnes NC. Airway mucosal inflammation in COPD is similar in smokers and ex-smokers: a pooled analysis. Eur Respir J 2007;30:467-471. (Pubitemid 351182069)
32. Willemse BW, ten Hacken NH, Rutgers B, Lesman-Leegte IG, Postma DS, Timens W. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J 2005;26:835-845. (Pubitemid 41632040)
33. Watt AP, Schock BC, Ennis M. Neutrophils and eosinophils: clinical implications of their appearance, presence and disappearance in asthma and COPD. Curr Drug Targets Inflamm Allergy 2005;4:415-423. (Pubitemid 41052406)
34. Libert C, Van Molle W, Brouckaert P, Fiers W. Alpha1-Antitrypsin inhibits the lethal response to TNF in mice. J Immunol 1996;157:5126-5129. (Pubitemid 126449595)
35. Tanni SE, Pelegrino NR, Angeleli AY, Correa C, Godoy I. Smoking status and tumor necrosis factor-alpha mediated systemic inflammation in COPD patients. J Inflamm (Lond) 2010;7:29.
36. Pinto-Plata V, Toso J, Lee K, Park D, Bilello J, Mullerova H, De Souza MM, Vessey R, Celli B. Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax 2007;62:595-601. (Pubitemid 47056886)
37. Reichert V, Xue X, Bartscherer D, Jacobsen D, Fardellone C, Folan P, Kohn N, Talwar A, Metz CN. A pilot study to examine the effects of smoking cessation on serum markers of inflammation in women at risk for cardiovascular disease. Chest 2009;136:212-219.
38. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1997;1:1645-1648.
39. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 2009;9:271-285.
40. Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology 2010;49:1215-1228.